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New renal tubule cell therapy is 
found safe and lowers death rates 
in patients with acute renal failure
A prospective trial conducted at 12 clinical centers in the 
United States evaluates the impact of the renal tubular assist 
device (RAD) on all-cause mortality at 28 days among patients 
with acute renal failure. The RAD (RenaMed Biologics) is an 
extracorporeal circuit fabricated with a standard hemofiltra-
tion cartridge containing nonautologous human renal tubu-
lar cells grown along the inner surface of the hollow fibers 
and is incorporated in series with a separate hemofiltration 
cartridge. Animal studies of this device demonstrate that 
the cells retain transport, metabolic, and endocrine activi-
ties. Further, the two-cartridge system was found to replace 
filtration, transport, metabolic, and endocrine function in 
acutely uremic animals and to lessen multiorgan dysfunction 
in Gram-negative sepsis in large animals.
Tumlin et al. randomized 58 patients, 40 to the RAD and 18 
to continuous renal replacement therapy (CRRT) alone. Eli-
gible patients required CRRT for the treatment of acute renal 
failure due to acute tubular necrosis and had a history of at 
least one nonrenal organ failure or the presence of sepsis. At 
day 28, the mortality rate was significantly lower in the RAD 
group than in the CRRT group (33% versus 61%, respectively, 
P = 0.08, χ2; P = 0.03, log-rank (Figure)). The hazard ratio 
for death in the RAD group compared with the CRRT group 
was 0.481 (0.23–0.99), adjusting for disease cause. The point 
estimate for this hazard ratio was similar across subgroups 
stratified by age, race, and severity of illness. Also, a higher 
proportion of subjects in the RAD group recovered renal 
function (53%) as compared with the CRRT group (28%), 
but this did not reach conventional levels of statistical signifi-
cance. Although the study is limited by the number of subjects 
enrolled, no significant safety concerns were raised about the 
RAD.
Research to date focusing on the use of dialytic therapies 
has affected the staggering mortality rate among the criti-
cally ill with acute renal failure. Therapies that differ with 
respect to dialysis dose, frequency or modality, and type of 
membrane have not demonstrated consistent results. While 
the safety and feasibility of the RAD will be further explored 
in subsequent years, this study indicates that the RAD has 
the potential to impact mortality associated with acute renal 
failure. (J Am Soc Nephrol 2008; 19: 1034–1040; doi:10.1681/
ASN.2007080895)
Lynda Szczech
Adiponectin regulates glomerular 
permeability to albumin
The hormone adiponectin, a 30-kilodalton protein primarily 
secreted by adipocytes, circulates in plasma in multimeric 
forms ranging from trimers to high–molecular weight oli-
gomers containing 12- to 18-mers. It plays an important role 
in regulating insulin sensitivity, and its plasma level has been 
recently recognized as a predictive factor for cardiovascular 
mortality in patients with renal failure. Albuminuria is associ-
ated with obesity and diabetes and is a risk factor for cardiovas-
cular and renal disease in these conditions. However, the link 
between early albuminuria and adiposity remains unclear. In 
a recent study, Sharma et al. used clinical and laboratory work 
to examine whether adiponectin is a communication signal 
between adipocytes and the kidney. In a cohort of patients at 
high risk for diabetes and kidney disease, albuminuria had a 
negative correlation with plasma adiponectin in obese patients. 
Remarkably, adiponectin knockout (Ad–/–) mice had increased 
albuminuria and fusion of podocyte foot processes (Figure). 
Also, when the authors used a fragment of adiponectin that 
interacts with cellular adiponectin receptors and mimics many 
of the actions of the full-length hormone, it increased activity 
of 5′-AMP activated protein kinase (AMPK) in cultured podo-
cytes, and both adiponectin and AMPK activation reduced 
podocyte permeability to albumin and podocyte dysfunction. 
These effects appeared to be caused by a reduction in oxidative 
stress, as adiponectin and AMPK activation both reduced pro-
tein levels of the nicotinamide adenine dinucleotide phosphate 
oxidase Nox4. Finally, Ad–/– mice treated with adiponectin 
exhibited normalization of albuminuria, improved podocyte 
Kaplan-Meier estimates of survival for patients in the RAD and 
conventional CRRT groups.
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Kidneys of Ad–/– mice exhibit increased podocyte effacement (right) 
as compared with those of wild-type mice (left). Arrows denote areas 
of normal foot processes in wild-type mice and areas of foot process 
effacement in Ad–/–.
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foot process effacement, increased glomerular AMPK 
activation, and reduced urinary and glomerular markers of 
oxidant stress. These results suggest that adiponectin is a key 
regulator of glomerular permeability and that it has an impor-
tant role in the pathogenesis of albuminuria. (J Clin Invest 
2008; 118: 1645–1656; doi:10.1172/JCI32691)
Juan Oliver
Rare mutations in renal salt 
handling genes contribute to 
blood pressure variation
Although epidemiologic studies have long since demonstrated 
the high heritability of variations in blood pressure, identifica-
tion of the responsible genes has been difficult because of their 
trait’s complexity. Currently, it is unknown even whether com-
mon variants or many independent rare mutations account for 
the contributions of specific genes. Landmark studies of rare 
mendelian traits carried out mainly in R. Lifton’s laboratory 
identified more than 20 genes in which mutations impart large 
effects on blood pressure; most of these mutations appear to act 
by changing net renal salt reabsorption. Several of these disor-
ders, exemplified by Bartter’s and Gitelman’s syndromes, have 
recessive traits that lower blood pressure. These observations 
raise the interesting question of whether the more prevalent 
heterozygous mutations in these genes might commonly affect 
the trait. Bartter’s syndrome is caused by recessive loss-of-func-
tion mutations of the Na-K-2Cl cotransporter gene SLC12A1 
and of the inward rectifier K+ channel gene KCNJ1. Gitelman’s 
syndrome is a less severe salt-wasting disease caused by reces-
sive loss-of-function mutations in the NaCl cotransporter 
gene SLC12A3. The prevalence of Bartter’s and Gitelman’s 
syndromes (approximately 1 per million and 1 per 40,000, 
respectively) suggests that heterozygous disease alleles should 
be present in at least 1% of the population. In a recent com-
munication, Ji et al. reported analysis of these genes in a large, 
well-characterized cohort. They examined SLC12A1 (NKCC2), 
SLC12A3 (NCCT), and KCNJ1 (ROMK) in the Framingham 
Heart Study offspring cohort. This cohort, comprising 5,124 
subjects (3,125 for whom DNA samples have been obtained), 
has been followed for up to 35 years with periodic evalua-
tion of cardiovascular risk factors and other traits, permit-
ting stable assessments of quantitative trait values over time. 
Using comparative genomics, genetics, and biochemistry, the 
authors identified subjects with mutations proven or inferred 
to be functional. These mutations, all heterozygous and rare, 
produced clinically significant blood pressure reduction and 
protection from developing hypertension as the subjects aged 
(Figure). These important findings implicate rare alleles that 
alter renal salt handling in the variation of blood pressure in 
the general population, and they show that the carrier state of 
mutations that inactivate renal sodium transport significantly 
lowers blood pressure. These findings have serious implications 
for our understanding of hypertension genetics. (Nat Genet 
2008; 40: 592–599; doi:10.1038/ng.118)
Juan Oliver
Angiotensin II upregulates ACE, 
downregulates ACE2 via the  
AT1–ERK/p38 MAP kinase pathway
Approximately 30% of Americans have hypertension, making 
it one of the most important risk factors for cardiovascular 
disease and the major cause of mortality in the United States. 
The recent discovery of the angiotensin II (Ang II)-breakdown 
enzyme angiotensin I-converting enzyme (ACE) 2 suggests 
the importance of Ang II degradation in hypertension. Koka 
et al. explored the signaling mechanism by which ACE2 is reg-
ulated under hypertensive conditions. Real-time polymerase 
chain reaction and immunohistochemistry showed that ACE2 
mRNA and protein expression levels were high, whereas ACE 
expression levels were moderate in both the normal kidney 
and heart. In contrast, patients with hypertension showed ACE 
upregulation and ACE2 downregulation in both hypertensive 
cardiopathy and hypertensive nephropathy. The inhibition of 
ACE2 expression was associated with ACE upregulation and 
activation of extracellular signal-regulated kinase (ERK) 1/2 
and p38 mitogen-activated protein (MAP) kinase. In vitro, 
Ang II upregulated ACE and downregulated ACE2 in human 
kidney tubular cells, which were blocked by an angiotensin II 
type (AT) 1 receptor antagonist (losartan) but not by an AT2 
receptor blocker (PD123319). Furthermore, blockade of 
ERK1/2 or p38 MAP kinases by either specific inhibitors or 
a dominant-negative adenovirus abolished Ang II-induced 
ACE2 downregulation in human kidney tubular cells. In con-
clusion, Ang II upregulates ACE and downregulates ACE2 
expression levels under hypertensive conditions both in vivo 
and in vitro. The AT1 receptor-mediated ERK/p38 MAP 
kinase signaling pathway may be a key mechanism by which 
Ang II downregulates ACE2 expression, implicating an imbal-
ance of ACE/ACE2 in hypertensive cardiovascular and renal 
damage. (Am J Pathol 2008; 172: 1174–1183; doi:10.2353/
ajpath.2008.070762)
Marc De Broe 
Heterozygous mutations in SLC12A3, SLC12A1, and KCNJ1 lower blood 
pressure. Systolic blood pressure (SBP) among mutation carriers (red) 
and noncarriers (blue) at the last examination in different age groups.
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